Detecting tumour resistance to treatment with positron emission tomography

Tim's research focuses on the discovery and development of novel imaging methods to measure tumour resistance to therapy. The majority of cancer deaths result from ineffective treatment of metastatic disease due to either acquired or innate resistance to anti-cancer drugs. There is therefore an urgent unmet clinical need to develop biomarkers that can sensitively detect resistance to therapy early in a patient's treatment cycle. The early detection of treatment failure by noninvasive imaging will hopefully enable the selection of different drugs and more effective treatments, with the potential to substantially improve outcomes in this disease.